Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (August 2022)
34 slides from Sernova Biotherapeutics's investor presentation, August 2022

Slide 1: Advancing regenerative therapeutics to develop 'functional cures'
Advancing regenerative therapeutics to develop ‘functional cures’ August, 2022 Corporate Presentation 1

Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expects

Slide 3: Investment Highlights
Investment Highlights Proprietary Cell • Proprietary implantable device containing therapeutic cells in an organ-like environment Pouch System™ • Once implanted, is naturally vascularized allowing self-sustaining cell survival for years • Licensed program in local immuno-protection technology abroga

Slide 4: Sernova Executive Team and Board of Directors
SERNOVA Executive TEAM Dr. Philip M. TOLEIKIS Frank SHANNON David SWETLOW BA, MSc, PhD Vice President Clinical CPA, CA CEO, President, Director Development and Chief Financial Officer Regulatory Affairs Board of Directors Frank HOLLER Jeffrey BACHA Deborah BROWN James PARSONS Dr. Mohammad Dr. Philip

Slide 5: Sernova's Solution to Integrated Regenerative Medicine
Sernova’s Solution to Integrated Regenerative Medicine • Proprietary implantable medical device • Provides vascularized environment for • 1st generation utilizes human therapeutic cells to survive donor cells for long periods of time – • 2nd generation off-the-shelf creating an organ-like stem cell

Slide 6: Cell Pouch Containing Therapeutic Cells
Cell Pouch Containing Therapeutic Cells Biologically Compatible Delivery – Allows Natural Vascularization • Proprietary Cell Pouch placed • Therapeutic cells transplanted • Therapeutic cells responsive deep under the skin into the vascularized tissue to endogenous regulation chambers • Prepares an o

Slide 7: Cell Pouch - Overcoming Limitations of Predecessors
Cell Pouch - Overcoming Limitations of Predecessors An effective organ-like environment Human donor cells Tissue Vascularizes Stem cell-derived islet cells No Fibrosis Sernova Scalable Cell Pouch Natural cell environment Biocompatible Cell engraftment 7

Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications
Pipeline – Life Cycle Iterations and Multiple Indications Therapeutic Product Candidate Cell Source Immune Protection Indication Discovery Pre-Clinical Phase 1/2 Phase 3 BLA Human donor Immunosuppressives islet cells Type 1 Diabetes Human donor Local immune Cell Pouch System islet cells protection I

Slide 9: Cell Pouch System For Type 1 Diabetes
Cell Pouch System For Type 1 Diabetes

Slide 10: Diabetes: Global Disease = Global Market
DIABETES GLOBAL DISEASE = GLOBAL MARKET Diabetes is one of the most prevalent diseases and most pervasive medical problems impacting society and quality of life today. 537 million people are affected worldwide with diabetes; another estimated 179 million people have it without knowing it. By 2045, p

Slide 11: Lead Indication: Hypoglycemia Unawareness Among Type 1 Diabetic Patients
Lead Indication for Type 1 Diabetes Hypoglycemia Unawareness Among Type 1 Diabetic Patients Hypoglycemia Unawareness – most critical unmet need in T1D Affects 15% of T1D patients (~240k patients in the US) Clinically defined as a person’s inability to recognize the symptoms of low blood sugar before

Slide 12: Phase 1/2 Study Design – Ongoing
Phase 1/2 Study Design – Ongoing Patients with Type 1 Diabetes (T1D) and Hypoglycemia Unawareness Trial Overview • Open label, single-arm, single-center trial (n=7) • Insulin-dependent T1D patients with hypoglycemia unawareness Study • Cell Pouch implant followed by 2 sequential human donor islet tr

Slide 13: Phase 1/2 Study – Current Patient Status and Design
Phase 1/2 Study – Current Patient Status and Design Primary Study Follow-up Baseline 1 MO +1 MO +6-12 MO +6-12 MO Ongoing Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 13

Slide 14: Phase 1/2 Interim Results – ADA Presentation June 2022
Phase 1/2 Interim Results – ADA Presentation June 2022 • Surgical implantation of the Cell Pouch was found to be generally well tolerated with a favorable safety profile • All patients who had favorable immunosuppression achieved complete insulin independence • The first three transplanted patients

Slide 15: Phase 1/2 Individual Patient Assessments – ADA June 2022
Phase 1/2 Individual Patient Assessments – ADA June 2022 First Three Patients Patient 1 • Insulin independent at 2-year follow-up after Cell Pouch islet Tx and intraportal islet Tx • Positive for stimulated serum C-peptide after 1st Tx into Cell Pouch • HbA1c – 5.0 Patient 2 • Insulin independent at

Slide 16: Sentinel Cell Pouch Histology Results - 90 Days Post-TX
Sentinel Cell Pouch Histology Results - 90 Days Post-TX Sentinel Cell Pouch Sentinel Cell Pouch vWF+ DAPI Insulin + vWF + DAPI Insulin + vWF + DAPI Insulin +Somatostatin+ DAPI f f e e d 4x 20x d 4x 10x c c b b a a Insulin + Glucagon + DAPI Insulin +Somatostatin+ DAPI C-peptide + DAPI Insulin + CK-19

Slide 17: Patient #1 – Impact Statement
Patient #1 – Impact Statement After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how to manage my diabetes.

Slide 18: Evotec Partnership For Insulin-Producing Stem Cells
Evotec Partnership For Insulin-Producing Stem Cells

Slide 19: Abundant Supply of Insulin-Producing Human iPSC's
Abundant Supply of Insulin-Producing Human iPSC’s • May 2022: acquired option for exclusive global license to Evotec’s Induced Pluripotent Stem Cell (iPSC)-based human beta cells for use with its Cell Pouch System or alone with other technologies • Access to unlimited supply of insulin-producing isl

Slide 20: Strong Strategic Fit to Advance Potential 'Functional Cure' for Diabetes
Strong Strategic Fit to Advance Potential ‘Functional Cure’ for Diabetes Partnership and licensing option agreement to enable a potential ‘functional cure’ for insulin-dependent diabetes without supply constraints Cell Pouch System™ • Implantable medical device / • iPSC-based islet-like immune prote

Slide 21: E.iBETA Delivers Long-Term Efficacy in Preclinical Models
E.iBETA Delivers Long-Term Efficacy in Preclinical Models High quality cell composition coupled with robust production process E.iBeta generated from a GMP iPSC line in bioreactor Long-term normalization of blood glucose in diabetic mice following E.iBeta transplantation Microscopy Histology C-PEPTI

Slide 22: Cell Pouch System – Progress and 2022-2023 Goals
Cell Pouch System – Progress and 2022-2023 Goals Internal and External Advancement of Development and Commercialization Strategy Diabetes Program Next T1D Technology Therapeutic Product Development • Advance Sernova / Evotec Partnership E.iBETA iPSC-based islets in Cell Pouch as an off-the-shelf pro

Slide 23: Conformal Coating For Cellular Immune Protection
Conformal Coating For Cellular Immune Protection

Slide 24: Conformal Coating Technology – for Immune Protection
Conformal Coating Technology – for Immune Protection • ‘Shrink wrap’ properties • Thin biocompatible cross-linked allows volume of transplanted polymer hydrogel coating that cells into the Cell Pouch to be surrounds therapeutic cells Conformal Coating – unaffected University of Miami / Sernova Colla

Slide 25: Conformal Coating Technology for Cellular Immune Protection
Conformal Coating Technology for Cellular Immune Protection University of Miami / Sernova Collaboration Preliminary Results Conformally Coated Rat Islet Isolated Rat Islets Conformal Coated Naked PEG, DAPI (nucleus) H&E staining of transplanted islets in Cell Pouch™ Naked islets in Cell Pouch™ Confo

Slide 26: Conformal Coating + Cell Pouch: Summary of Key Findings
Conformal Coating + Cell Pouch: Summary of Key Findings Conformal Cell Pouch + Coating with Immuno-protection Summary Cells Cells Safety in non-human primates • Volume of transplanted cells is unaffected • Distinct from other encapsulation methods, allows for Efficacy with donor islets in T1D pr

Slide 27: Additional Pipeline Assets
Additional Pipeline Assets • Hypothyroidism • Hemophilia A

Slide 28: Cell Pouch System for Hypothyroidism
Cell Pouch System for Hypothyroidism Therapeutic Benefits & Estimated Market ➔ 150,000 thyroidectomies performed annually just in the US Estimated Market ➔ $2.2B market opportunity Size ➔ Potential near-term revenue with patient own tissue ➔ Stem cell-derived technology for treatment of broad popula

Slide 29: Validation of Cell Pouch System for Hypothyroidism
Validation of Cell Pouch System for Hypothyroidism 29

Slide 30: Cell Pouch System Rare Disease Program – Hemophilia A
Cell Pouch System Rare Disease Program – Hemophilia A Therapeutic Benefits & Estimated Market ➔ 20,000 patients across North America and EU Estimated Market ➔ $10B orphan indication Size ➔ First generation • AUTOGRAFT: Patient’s own blood outgrowth endothelial cells (BOEC) are isolated, expanded and

Slide 31: Preclinical POC for Hemophilia A
Preclinical POC for Hemophilia A Preclinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Human factor VIII- corrected blood outgrowth endothelial cells (BOECs) were implanted within the Cell Pouch in a hemophilia A murine model Confirmed Release- Non-transplanted Cell Non-transpla

Slide 32: Validation of Cell Pouch System for Hemophilia A
Validation of Cell Pouch System for Hemophilia A 32

Slide 33: Summary – Advancing Towards Multiple Near-Term Catalysts
Summary – Advancing Towards Multiple Near-Term Catalysts • Complete regenerative medicine package for insulin-dependent diabetes Proprietary Device • Advancing programs for hypothyroidism and hemophilia A to clinic • Cell Pouch System able to treat multiple human afflictions where the body is defici

Slide 34: Head Office, Investor Relations, Business Development
Business Development Investor Relations Dr. Philip Toleikis Head Office Christopher Barnes VP, Investor Relations 1.519.858.5184 700 Collip Circle, Ste 114 philip.toleikis@sernova.com 1.519.902.7923 London, ON, Canada N6G 4X8 christopher.barnes@sernova.com Tel: 1.877.299.4603 Tel: 1.519.858.5184 Cor
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023